The Two Pillars of NMO Treatment

Treatment for Neuromyelitis Optica Spectrum Disorder (NMOSD) falls into two broad strategies: acute attack management (stopping an ongoing relapse as quickly as possible) and long-term prevention (reducing the frequency and severity of future relapses). Because NMO is primarily a relapsing disease, both pillars are essential — neurological damage accumulated during attacks is often permanent, making prevention especially critical.

Treating Acute Attacks

High-Dose Intravenous Corticosteroids

The first-line treatment for an acute NMO attack is intravenous methylprednisolone, typically administered at 1,000 mg per day for three to five days. Steroids rapidly reduce inflammation, limiting the extent of damage to the optic nerves and spinal cord. While they often produce partial recovery, the residual deficit may remain significant — particularly in severe attacks.

Plasma Exchange (Plasmapheresis / PLEX)

When attacks are severe or steroid-unresponsive, plasma exchange is the key rescue therapy. PLEX works by physically removing circulating pathogenic antibodies (including AQP4-IgG) from the blood, replacing the plasma with albumin or fresh frozen plasma. It is typically performed over five to seven sessions and has demonstrated meaningful recovery benefits when used early in severe attacks.

Intravenous Immunoglobulin (IVIg)

IVIg is sometimes used as an alternative or adjunct in acute management, though evidence is less robust than for steroids and PLEX. It may have a role in patients who cannot tolerate plasmapheresis.

Long-Term Relapse Prevention

Given that each NMO relapse can cause irreversible neurological damage, virtually all patients with confirmed NMOSD should be on long-term preventive therapy. The treatment landscape has changed dramatically in recent years with the approval of targeted biologic agents.

FDA-Approved Biologics (AQP4-IgG Positive NMOSD)

  • Eculizumab (Soliris): A complement inhibitor that blocks the complement cascade implicated in NMO-related tissue destruction. Approved by the FDA in 2019, it was the first biologic specifically approved for NMOSD.
  • Inebilizumab (Uplizna): An anti-CD19 B-cell depleting monoclonal antibody, FDA-approved in 2020. It targets B cells (the producers of AQP4-IgG antibodies) more broadly than anti-CD20 agents.
  • Satralizumab (Enspryng): An IL-6 receptor antagonist that blocks interleukin-6 signaling, a key inflammatory pathway in NMO. Approved in 2020, it is available as a subcutaneous injection for patient self-administration.
  • Ublituximab (Briumvi): Approved for MS, also being studied in NMOSD contexts — not yet specifically approved for NMOSD.

Traditional Immunosuppressants (Off-Label but Widely Used)

Before the biologic era, and still used in resource-limited settings or for AQP4-negative patients, the following agents have a long track record:

  • Rituximab: An anti-CD20 B-cell depleting agent; widely used off-label and considered a standard of care in many centers globally.
  • Mycophenolate mofetil (CellCept): An immunosuppressant that reduces lymphocyte proliferation.
  • Azathioprine (Imuran): Often combined with low-dose oral corticosteroids for maintenance immunosuppression.

Treatment Considerations for MOG-IgG Associated Disease (MOGAD)

Patients with MOG-antibody disease require careful consideration — the evidence base for MOGAD-specific treatment is still developing. Many patients respond well to steroids and have a more favorable relapse recovery than AQP4-positive NMOSD, though long-term immunosuppression is still often recommended for those with recurring attacks.

Monitoring and Safety

All NMO therapies carry potential risks that require regular monitoring:

  • Infection risk with B-cell depleting therapies — vaccination schedules must be updated before starting treatment
  • Eculizumab requires meningococcal vaccination due to increased meningococcal infection risk
  • Liver function and blood counts for azathioprine and mycophenolate
  • Regular MRI and antibody titer monitoring to assess treatment response

The Importance of an NMO Specialist

NMO is rare enough that treatment decisions should ideally involve a neurologist with expertise in neuroimmunology or NMOSD. Treatment decisions — particularly which biologic to choose — depend on antibody status, comorbidities, lifestyle factors (such as pregnancy planning), and access considerations.